Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

LEAP-005 Results at ESMO 2020

Abstract No : Abstract #LBA41

Indication : Gastric Cancer, Colorectal Cancer, Biliary tract cancer, Glioblastoma, Ovarian Cancer, Breast cancer

Intervention : Lenvatinib

Company : Merck & Co.

Technology : multiTKI


Results:

187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable


Conclusion:

187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable


Executive Summary

In the interim analysis, prespecified futility efficacy criteria for cohort expansion were met or exceeded, toxicity were manageable in all cohorts. In gastric cancer, ORR: 10%, DCR: 48%. Median PFS: 2.5 months, 6-month rate: 22.2%. Current results show promising efficacy and warrants further randomized trials.

Recent Articles